Broadwood Partners SC 13D/A Staar Surgical Co

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13D/A

THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 19)

STAAR Surgical Company

(Name of Issuer)

Common Stock

(Title of Class of Securities)

852312305

(CUSIP Number)

Neal C. Bradsher

c/o Broadwood Capital, Inc.

724 Fifth Avenue, 9th Floor

New York, New York 10019

(Name, Address and Telephone Number of Person Authorized to Receive

Notices and Communications)

January 26, 2016

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13D-1(e), 240.13d‑1(f) or 240.13d-1(g), check the following box [ ].

CUSIP No.

852312305

1.	NAME OF REPORTING PERSONS
	Broadwood Partners, L.P.

2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
		(a) [_]
		(b) [X]

3.	SEC USE ONLY


4.	SOURCE OF FUNDS

	WC

5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)	[_]

6.	CITIZENSHIP OR PLACE OF ORGANIZATION

	Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
7.	SOLE VOTING POWER

	0

8.	SHARED VOTING POWER

	9,649,557

9.	SOLE DISPOSITIVE POWER

	0

10.	SHARED DISPOSITIVE POWER

	9,649,557

11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

	9,649,557

12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
	CERTAIN SHARES	[_]


13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

	24.2%

14.	TYPE OF REPORTING PERSON

	PN

CUSIP No.

852312305

1.	NAME OF REPORTING PERSONS

	Broadwood Capital, Inc.

2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
		(a) [_]
		(b) [X]

3.	SEC USE ONLY


4.	SOURCE OF FUNDS

	AF

5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)	[_]


6.	CITIZENSHIP OR PLACE OF ORGANIZATION

	New York

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

7.	SOLE VOTING POWER

	0

8.	SHARED VOTING POWER

	9,649,557

9.	SOLE DISPOSITIVE POWER

	0

10.	SHARED DISPOSITIVE POWER

	9,649,557

11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

	9,649,557

12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
	CERTAIN SHARES


13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
		[_]
	24.2%

14.	TYPE OF REPORTING PERSON

	CO, IA

CUSIP No.

852312305

1.	NAME OF REPORTING PERSONS

	Neal C. Bradsher

2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
		(a) [_]
		(b) [X]
3.	SEC USE ONLY


4.	SOURCE OF FUNDS

	WC, AF, OO

5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)	[_]


6.	CITIZENSHIP OR PLACE OF ORGANIZATION

	United States of America

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

7.	SOLE VOTING POWER

	25,900

8.	SHARED VOTING POWER

	9,649,557

9.	SOLE DISPOSITIVE POWER

	25,900

10.	SHARED DISPOSITIVE POWER

	9,649,557

11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
	PERSON

	9,675,457

12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
	CERTAIN SHARES	[_]


13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

	24.3%

14.	TYPE OF REPORTING PERSON

	IN

CUSIP No.	852312305

	This Amendment No. 19 to this Schedule 13D is being filed to correct a clerical error. Amendment No. 18 was inadvertently filed with Neal C. Bradsher as the Reporting Person on EDGAR instead of Broadwood Partners, L.P. This Amendment No. 19 is being filed with Broadwood Partners, L.P. as the Reporting Person on EDGAR. There are no other differences between Amendment No. 19 and Amendment No. 18.

Item 1.	Security and Issuer.

	STAAR Surgical Company, Common Stock, par value $0.01 per share (the "Shares") STAAR Surgical Company 1911 Walker Avenue Monrovia, California 91016

Item 2.	Identity and Background.

	NO MATERIAL CHANGE FROM THE SCHEDULE 13D/A FILED ON JUNE 28, 2010.

Item 3.	Source and Amount of Funds or Other Consideration.
	As of the date hereof Broadwood Partners may be deemed to beneficially own 9,649,557 Shares. As of the date hereof Broadwood Capital may be deemed to beneficially own 9,649,557 Shares. As of the date hereof Neal C. Bradsher may be deemed to beneficially own 9,675,457 Shares. No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes in the ordinary course of business.

Item 4.	Purpose of Transaction.

	The Reporting Persons acquired their Shares of the Issuer for investment purposes.

	The Reporting Persons have no plans or proposals which, other than as expressly set forth below, would relate to or would result in: (a) the acquisition of additional securities of the Issuer or the disposition of presently-owned securities of the Issuer; (b) any extraordinary corporate transaction involving the Issuer; (c) a sale or transfer of a material amount of assets of the Issuer; (d) any change in the present Board of Directors or management of the Issuer; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any material change in the operating policies or corporate structure of the Issuer; (g) any change in the Issuer's charter or by-laws; (h) the Shares of the Issuer ceasing to be authorized to be quoted in the over-the-counter security markets; or (i) causing the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934. The Reporting Persons, however, reserve the right, at a later date, to effect one or more of such changes or transactions in the number of shares they may be deemed to beneficially own.
	The Reporting Persons have been and may continue to be in contact with members of the Issuer's management, the Issuer's Board of Directors, other significant shareholders and others regarding alternatives that the Issuer could employ to improve shareholder value.

	The Reporting Persons believe that the Issuer's improved management team is continuing to make progress in overcoming the Issuer's previous setbacks and is addressing some of the obstacles that have prevented the Issuer from realizing its substantial long-term growth opportunity. In light of this progress, and consistent with the Reporting Persons' longstanding belief in the Issuer's proprietary technology and substantial growth opportunity, the Reporting Persons recently increased their ownership of the Issuer's shares. The Reporting Persons also were pleased to learn of additional tangible evidence of the Issuer's business progress from its recent disclosure that it has signed agreements with large customers and expects robust unit growth and gross margin improvement from its main product line in 2016.

The Reporting Persons are also encouraged by the Issuer's progress with respect to certain corporate governance matters, and recognizes the effort that has resulted in the progress that has been made so far. However, the Reporting Persons remain concerned that while the Issuer's Board of Directors has improved somewhat, its Board's alignment with and representation of the Issuer's shareholders are still inadequate. The results of the Issuer's shareholders' votes at the Issuer's most recent annual meeting made clear that shareholders do not support certain members of the current Board. The Reporting Persons are encouraged that there have been three subsequent improvements to the Board, including most recently the appointment of Mr. Farrell, who has a long record of involvement in shareholder-oriented corporate governance and the creation of large amounts of shareholder value. However, these changes represent only slow and limited progress toward a board that is aligned with and represents the Issuer's shareholders. The Reporting Persons believe that additional progress is needed in order for shareholders to have confidence that the recent changes will lead to a Board that is aligned with and represents the Issuer's shareholders. The Reporting Persons intend to remain in dialogue with members of the Board and other shareholders about potential further improvements to the Board and the Issuer's corporate governance.

Item 5.	Interest in Securities of the Issuer.

(a, b)	As of the date hereof, Broadwood Partners may be deemed to be the beneficial owner of 9,649,557 Shares, constituting 24.2% of the Shares of the Issuer, based upon the 39,888,716 Shares outstanding as of October 23, 2015.

	Broadwood Partners has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 9,649,557 Shares; has sole power to dispose or direct the disposition of 0 Shares; and has shared power to dispose or direct the disposition of 9,649,557 Shares.

(a, b)	As of the date hereof, Broadwood Capital may be deemed to be the beneficial owner of 9,649,557 Shares, constituting 24.2% of the Shares of the Issuer, based upon the 39,888,716 Shares outstanding as of October 23, 2015. Broadwood Capital has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 9,649,557 Shares; has sole power to dispose or direct the disposition of 0 Shares; and has shared power to dispose or direct the disposition of 9,649,557 Shares. Broadwood Capital specifically disclaims beneficial ownership in the Shares reported herein except to the extent of its pecuniary interest therein.

(a, b)	As of the date hereof, Neal C. Bradsher may be deemed to be the beneficial owner of 9,675,457 Shares, constituting 24.3% of the Shares of the Issuer, based upon the 39,888,716 Shares outstanding as of October 23, 2015. Neal C. Bradsher has the sole power to vote or direct the vote of 25,900 Shares; has the shared power to vote or direct the vote of 9,649,557 Shares; has sole power to dispose or direct the disposition of 25,900 Shares; and has shared power to dispose or direct the disposition of 9,649,557 Shares. Neal C. Bradsher specifically disclaims beneficial ownership in the Shares reported herein except to the extent of his pecuniary interest therein.

(c)	The trading dates, number of Shares purchased and sold and price per share for all transactions in the Shares by the Reporting Persons since the most recent filing of Schedule 13D are set forth in Exhibit B and all such transactions were effected in open market transactions.

Item 6.	Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
	N/A

Item 7.	Material to be Filed as Exhibits.

	Exhibit A: Joint Filing Agreement. Exhibit B: Transactions by the Reporting Persons since the most recent filing of Schedule 13D.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	BROADWOOD PARTNERS, L.P.
	By:	Broadwood Capital, Inc.

	By:	/s/ Neal C. Bradsher
	Name:	Neal C. Bradsher
	Title:	President


	BROADWOOD CAPITAL, INC.*

	By:	/s/ Neal C. Bradsher
	Name:	Neal C. Bradsher
	Title:	President


	/s/ Neal C. Bradsher
	NEAL C. BRADSHER *

	February 2, 2016

* The Reporting Persons disclaim beneficial ownership over the securities reported herein except to the extent of the reporting persons' pecuniary interest therein.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

Exhibit A

Joint Filing Agreement

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of STAAR Surgical Company.

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

Executed this 2nd day of February, 2016.

	BROADWOOD PARTNERS, L.P.
	By:	Broadwood Capital, Inc.

	By:	/s/ Neal C. Bradsher
	Name:	Neal C. Bradsher
	Title:	President


	BROADWOOD CAPITAL, INC.

	By:	/s/ Neal C. Bradsher
	Name:	Neal C. Bradsher
	Title:	President


	/s/ Neal C. Bradsher
	NEAL C. BRADSHER

Exhibit B

Transactions by the Reporting Persons since the most recent filing of Schedule 13D

TRANSACTIONS IN THE SHARES

Date of Transaction	Number of Shares Purchase/(Sold)	Price of Shares
1/13/2016	34,500	$6.7727¹

1/14/2016	9,491	$6.79

1/15/2016	91,734	$6.705²

1/19/2016	32,937	$6.7687³

1/20/2016	39,921	$6.7303⁴

1/25/2016	81,752	$6.74⁵

1/26/2016	112,900	$6.6002⁶

1/27/2016	44,361	$6.5289⁷

1/28/2016	13,742	$6.4692⁸

1/29/2016	40,231	$6.485⁹

2/1/2016	12,010	$6.481¹⁰

¹ This constitutes the weighted average purchase price. The prices range from $6.64 to $6.79. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

² This constitutes the weighted average purchase price. The prices range from $6.57 to $6.79. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

³ This constitutes the weighted average purchase price. The prices range from $6.69 to $6.79. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

⁴ This constitutes the weighted average purchase price. The prices range from $6.71 to $6.74. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

⁵ This constitutes the weighted average purchase price. The prices range from $6.73 to $6.74. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

⁶ This constitutes the weighted average purchase price. The prices range from $6.60 to $6.705. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

⁷ This constitutes the weighted average purchase price. The prices range from $6.49 to $6.56. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

⁸ This constitutes the weighted average purchase price. The prices range from $6.44 to $6.50. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

⁹ This constitutes the weighted average purchase price. The prices range from $6.465 to $6.50. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

¹⁰ This constitutes the weighted average purchase price. The prices range from $6.42 to $6.49. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SK 22056 0001 7033995

Broadwood Partners SC 13D/AStaar Surgical Co